$REFR
RESEARCH FRONTIERS INC

2013 Q3 Form 10-Q Financial Statement

#000120677413002692 Filed on August 06, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q2
Revenue $506.7K $521.8K $450.8K
YoY Change 7.38% 15.75% 222.02%
Cost Of Revenue $1.000M $970.0K $850.0K
YoY Change 3.09% 14.12% 14.86%
Gross Profit -$500.0K -$450.0K -$400.0K
YoY Change 0.0% 12.5% -33.33%
Gross Profit Margin -98.68% -86.23% -88.73%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $424.8K $394.3K $391.7K
YoY Change 15.0% 0.67% 18.68%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $1.427M $1.312M $1.244M
YoY Change 6.39% 5.52% 288.71%
Operating Profit -$920.7K -$826.9K -$793.0K
YoY Change 5.85% 4.27% -14.12%
Interest Expense $10.00K $10.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$860.0K -$779.5K -$789.6K
YoY Change -0.75% -1.28% -14.18%
Income Tax
% Of Pretax Income
Net Earnings -$911.1K -$815.8K -$789.6K
YoY Change 5.16% 3.32% -14.1%
Net Earnings / Revenue -179.82% -156.32% -175.13%
Basic Earnings Per Share
Diluted Earnings Per Share -$39.70K -$35.82K -$41.78K
COMMON SHARES
Basic Shares Outstanding 22.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.17M $12.09M $2.890M
YoY Change 23.84% 318.34% -47.74%
Cash & Equivalents $6.108M $7.030M $1.839M
Short-Term Investments $5.060M $5.060M $1.050M
Other Short-Term Assets $70.00K $60.00K $50.00K
YoY Change 0.0% 20.0% -54.55%
Inventory
Prepaid Expenses
Receivables $964.1K $839.2K $540.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.21M $12.99M $3.480M
YoY Change 26.36% 273.37% -41.02%
LONG-TERM ASSETS
Property, Plant & Equipment $70.12K $72.92K $70.00K
YoY Change 0.17% 4.17% -30.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $20.00K $20.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $92.73K $95.52K $90.00K
YoY Change 3.03% 6.14% -25.0%
TOTAL ASSETS
Total Short-Term Assets $12.21M $12.99M $3.480M
Total Long-Term Assets $92.73K $95.52K $90.00K
Total Assets $12.30M $13.09M $3.570M
YoY Change 26.14% 266.63% -40.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $61.24K $111.3K $170.0K
YoY Change -56.26% -34.55% 112.5%
Accrued Expenses $130.0K $130.0K $140.0K
YoY Change 8.33% -7.14% 7.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $255.2K $367.3K $470.0K
YoY Change -24.95% -21.84% 17.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $255.2K $367.3K $470.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $260.0K $370.0K $470.0K
YoY Change -23.53% -21.28% 17.5%
SHAREHOLDERS EQUITY
Retained Earnings -$90.70M -$89.84M
YoY Change
Common Stock $102.7M $102.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.04M $12.72M $3.100M
YoY Change
Total Liabilities & Shareholders Equity $12.30M $13.09M $3.570M
YoY Change 26.14% 266.63% -40.7%

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$911.1K -$815.8K -$789.6K
YoY Change 5.16% 3.32% -14.1%
Depreciation, Depletion And Amortization $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities -$910.0K -$760.0K -$200.0K
YoY Change 8.33% 280.0% -75.61%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$30.00K $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$10.00K $210.0K
YoY Change -104.76% -110.5%
Cash From Investing Activities -$10.00K -$30.00K $210.0K
YoY Change 0.0% -114.29% -110.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -910.0K -760.0K -200.0K
Cash From Investing Activities -10.00K -30.00K 210.0K
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -920.0K -790.0K 10.00K
YoY Change -115.03% -8000.0% -100.35%
FREE CASH FLOW
Cash From Operating Activities -$910.0K -$760.0K -$200.0K
Capital Expenditures $0.00 -$30.00K $0.00
Free Cash Flow -$910.0K -$730.0K -$200.0K
YoY Change 9.64% 265.0% -75.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000793524
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22916095 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
RESEARCH FRONTIERS INC
CY2013Q2 refr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
128567 USD
CY2012Q4 refr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
145123 USD
CY2013Q2 refr Deposits And Other Assets Non Current
DepositsAndOtherAssetsNonCurrent
22605 USD
CY2012Q4 refr Deposits And Other Assets Non Current
DepositsAndOtherAssetsNonCurrent
22605 USD
CY2012Q2 refr Note Receivable Conversion Rate
NoteReceivableConversionRate
0.10
CY2010Q2 refr Note Receivable Conversion Rate
NoteReceivableConversionRate
0.25
refr Note Receivable Maturity Date
NoteReceivableMaturityDate
2012-05-09
CY2013Q2 refr Note Receivable Stated Interest Rate
NoteReceivableStatedInterestRate
0.1 pure
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
111272 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
72269 USD
CY2013Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
839169 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
688318 USD
CY2013Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
102559702 USD
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
101642297 USD
CY2013Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
92723 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
92723 USD
CY2013Q2 us-gaap Assets
Assets
13088783 USD
CY2012Q4 us-gaap Assets
Assets
14415067 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
12993261 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
14333421 USD
us-gaap Basis Of Accounting
BasisOfAccounting
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: left"><u style="font-family: Times New Roman; font-size: 80%">Basis of Presentation</u></p> <p style="font-family: Times New Roman; font-size: 80%; text-align: justify"> The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the three and six months ended June 30, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2013. For further information, refer to the consolidated financial statements and footnotes thereto included in the Annual Report on Form 10-K relating to Research Frontiers Incorporated (the "Company") for the fiscal year ended December 31, 2012.</p> <!--EndFragment--></div> </div>
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7030474 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8390233 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1838691 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2403364 USD
CY2013Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
7000000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1359759 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-564673 USD
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22916095 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22646782 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22916095 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22646782 shares
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
2293 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
2265 USD
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
127500 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21867 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17122 USD
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
918192 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2586023 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
852217 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2291591 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-779480 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2368664 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-789551 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2206268 USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-613397 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
22447 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
32097 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
150851 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
203201 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
102500 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
131250 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-132302 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-43769 USD
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
11156 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
19008 USD
CY2012Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3490 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
21307 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13088783 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14415067 USD
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
367339 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
242392 USD
CY2013Q2 us-gaap Licenses Revenue
LicensesRevenue
521844 USD
us-gaap Licenses Revenue
LicensesRevenue
1229075 USD
CY2012Q2 us-gaap Licenses Revenue
LicensesRevenue
450828 USD
us-gaap Licenses Revenue
LicensesRevenue
933406 USD
us-gaap Loans And Leases Receivable Commitments Fixed Rates
LoansAndLeasesReceivableCommitmentsFixedRates
150000 USD
us-gaap Nature Of Operations
NatureOfOperations
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="text-align: justify"><u style="font-family: Times New Roman; font-size: 80%">Business</u></p> <p style="font-family: Times New Roman; font-size: 80%; text-align: justify"> Research Frontiers Incorporated ("Research Frontiers" or the "Company") operates in a single business segment which is engaged in the development and marketing of technology and devices to control the flow of light. Such devices, often referred to as "light valves" or suspended particle devices (SPDs), use colloidal particles that are either incorporated within a liquid suspension or a film, which is usually enclosed between two sheets of glass or plastic having transparent, electrically conductive coatings on the facing surfaces thereof. At least one of the two sheets is transparent. SPD technology, made possible by a flexible light-control film invented by Research Frontiers, allows the user to instantly and precisely control the shading of glass/plastic manually or automatically. SPD technology has numerous product applications, including: SPD-Smart&trade; windows, sunshades, skylights and interior partitions for homes and buildings; automotive windows; sunroofs, sun-visors, sunshades, rear-view mirrors, instrument panels and navigation systems; aircraft windows; eyewear products; and flat panel displays for electronic products. SPD-Smart light control film is now being developed for, or used in, architectural, automotive, marine, aerospace and appliance applications.</p> <p style="font-family: Times New Roman; font-size: 80%; text-align: justify"> The Company has historically utilized its cash and the proceeds from the sale of its investments to fund its research and development of SPD light valves, for marketing initiatives, and for other working capital purposes. The Company&#39;s working capital and capital requirements depend upon numerous factors, including the results of research and development activities, competitive and technological developments, the timing and cost of patent filings, and the development of new licensees and changes in the Company&#39;s relationships with its existing licensees. The degree of dependence of the Company&#39;s working capital requirements on each of the forgoing factors cannot be quantified; increased research and development activities and related costs would increase such requirements; the addition of new licensees may provide additional working capital or working capital requirements, and changes in relationships with existing licensees would have a favorable or negative impact depending on the nature of such changes. There can be no assurance that expenditures will not exceed the anticipated amounts or that additional financing, if required, will be available when needed or, if available, that&#39;s its terms will be favorable or acceptable to the Company. Eventual success of the Company and generation of <font style="font-family: Times New Roman; font-size: 80%">positive cash flow will be dependent upon the commercialization of products using the Company&#39;s technology by the Company&#39;s licensees and payments of continuing royalties on account thereof. To date, the Company has not generated sufficient revenue from its licensees to fund its operations.</font></p> <!--EndFragment--></div> </div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
72917 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59041 USD
CY2013Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
5059456 USD
CY2012Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
5052921 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42278 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
425441 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1317481 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-990114 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-779480 USD
us-gaap Net Income Loss
NetIncomeLoss
-2368664 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-789551 USD
us-gaap Net Income Loss
NetIncomeLoss
-1592871 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
1312480 USD
us-gaap Operating Expenses
OperatingExpenses
3616747 USD
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
1243869 USD
us-gaap Operating Expenses
OperatingExpenses
3160981 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-790636 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2387672 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-793041 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2227575 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35743 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4518 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
6535 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
-205056 USD
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
64162 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
201949 USD
CY2012Q1 us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
224903 USD
us-gaap Professional Fees
ProfessionalFees
61340 USD
us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
USD
us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
224903 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
394288 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1030724 USD
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
391652 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
869390 USD
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89840551 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-87471887 USD
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
0.003 pure
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
12721444 USD
us-gaap Share Based Compensation
ShareBasedCompensation
922918 USD
us-gaap Share Based Compensation
ShareBasedCompensation
581720 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.71 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.008 pure
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1
P5Y
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1
P5Y
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
0.51 pure
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
0.53 pure
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
0.003 pure
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
14172675 USD
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22916095 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22916095 shares
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18907555 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18907555 shares

Files In Submission

Name View Source Status
0001206774-13-002692-index-headers.html Edgar Link pending
0001206774-13-002692-index.html Edgar Link pending
0001206774-13-002692.txt Edgar Link pending
0001206774-13-002692-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
refr-20130630.xml Edgar Link completed
refr-20130630.xsd Edgar Link pending
refr-20130630_cal.xml Edgar Link unprocessable
refr-20130630_def.xml Edgar Link unprocessable
refr-20130630_lab.xml Edgar Link unprocessable
refr-20130630_pre.xml Edgar Link unprocessable
report.css Edgar Link pending
research_10q.htm Edgar Link pending
Show.js Edgar Link pending